New inhaled drug aims to help patients with lung scarring and high blood pressure
Disease control
Paused
This phase 3 trial tests an inhaled drug called seralutinib for people with pulmonary hypertension (high blood pressure in the lungs) caused by interstitial lung disease (lung scarring). About 480 adults will receive either seralutinib or a placebo for 24 weeks, followed by a lon…
Phase 3 • Sponsor: GB002, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC